Formycon AG (ETR:FYB)
29.90
+1.65 (5.84%)
Jun 26, 2025, 5:26 PM CET
Formycon AG Revenue
In the year 2024, Formycon AG had annual revenue of 69.67M EUR, down -10.32%. Formycon AG had revenue of 42.78M in the half year ending December 31, 2024, with 72.14% growth.
Revenue
69.67M
Revenue Growth
-10.32%
P/S Ratio
7.50
Revenue / Employee
278.70K
Employees
250
Market Cap
522.64M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 69.67M | -8.02M | -10.32% |
Dec 31, 2023 | 77.70M | 35.20M | 82.83% |
Dec 31, 2022 | 42.50M | 5.88M | 16.07% |
Dec 31, 2021 | 36.61M | 2.32M | 6.76% |
Dec 31, 2020 | 34.30M | 1.14M | 3.43% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.14B |
Merck KGaA | 21.32B |
Bayer Aktiengesellschaft | 46.58B |
Fresenius SE & Co. KGaA | 22.13B |
Fresenius Medical Care AG | 19.49B |
Sartorius Aktiengesellschaft | 3.44B |
Carl Zeiss Meditec AG | 2.17B |
Fielmann Group AG | 2.33B |
Formycon AG News
- 16 hours ago - EQS-News: Teva becomes secondary commercialization partner for Formycon's Stelara biosimilar FYB202 (ustekinumab) under the brand name Fymskina in Germany - Wallstreet:Online
- 1 day ago - EQS-News: U.S. biosimilar specialist Valorum Biologics LLC becomes commercialization partner for Formycon’s Eylea biosimilar FYB203/AHZANTIVE (aflibercept-mrbb) in the United States and Canada - Wallstreet:Online
- 2 days ago - EQS-News: Strong demand for Formycon 2025/2029 Bond leads to early closing of subscription period - Wallstreet:Online
- 6 days ago - EQS-News: Formycon bond 2025/2029: Public subscription now also possible via Deutsche Börse - Wallstreet:Online
- 8 days ago - EQS-News: Ordinary Annual General Meeting of Formycon AG approves all proposed resolutions by large majorities - Wallstreet:Online
- 8 days ago - EQS-News: Formycon AG: Subscription period for 2025/2029 corporate bond has started - Wallstreet:Online
- 9 days ago - EQS-News: Formycon plans public corporate bond issuance to support next growth phase within attractive Biosimilar markets - Wallstreet:Online
- 9 days ago - EQS-Adhoc: Formycon plans to issue a public senior unsecured floating rate bond with target volume of EUR 50 million to support further company growth - Wallstreet:Online